Last reviewed · How we verify
NCT04199520
Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients
Phase 2 trial testing surgery combined with systemic therapy in Stage IV Breast Cancer. Withdrawn.
1 May 2022
Quick facts
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 15 April 2020 |
| Primary completion | 1 May 2022 |
| Estimated completion | 1 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- surgery combined with systemic therapy
- systemic therapy — full drug profile →
Conditions studied
- Stage IV Breast Cancer — all drugs for Stage IV Breast Cancer →
Sponsor
Henan Cancer Hospital
Who can join
Adults 18 to 70, female only, with Stage IV Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare the effect of primary resection combined with systemic therapy and pure systemic therapy on the overall survival of patients with stage Ⅳ breast cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Role of Locoregional Treatment in De Novo Stage IV Breast Cancer.
Lee JS, Toktas O, Soran A. · · 2020 · cited 15× · PMID 32994701 · DOI 10.1177/1179554920942440
Verify or expand the search:
- PubMed search for NCT04199520
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stage IV Breast Cancer
Currently open trials in the same condition.
- NCT06678269 — A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer · Phase 1 · recruiting
- NCT06439693 — The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · Phase 2 · recruiting
- NCT05959291 — Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer · NA · recruiting
- NCT03971409 — Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurre · Phase 2 · active not recruiting
- NCT06361264 — Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide · EARLY_PHASE1 · recruiting
Other Henan Cancer Hospital trials
Trials by the same sponsor.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
- NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
- NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
- NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04199520 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
- Last refreshed: 4 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04199520.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing